Johnson & Johnson (JNJ) Declares $0.90 Quarterly Dividend; 2.9% Yield

UPDATE: Mylan (MYL), Sigmapharm Lose Challenge to Patent on Xarelto - Bloomberg

July 13, 2018 2:36 PM EDT

(Updated - July 13, 2018 2:38 PM EDT)

Bayer and Johnson & Johnson (NYSE: JNJ) won a trial court ruling that upheld the validity of a patent on blood-thinning drug Xarelto, according to Bloomberg.

Mylan (NASDAQ: MYL) and Sigmapharm failed to prove the patent shouldn't have been issued.

... More

Johnson & Johnson (JNJ) option implied volatility increases into EPS and outlook

July 13, 2018 12:26 PM EDT

Johnson & Johnson (NYSE: JNJ) July call option implied volatility is at 22, August is at 17; compared to its 52-week range of 11 to 28 into the expected release of EPS before the market open on July 17.

... More

Pre-Open Movers 07/13: (PIXY) (ADXS) (GLMD) Higher; (INGR) (JNJ) (T) Lower (more...)

July 13, 2018 8:53 AM EDT

Today's Pre-Open Movers

ShiftPixy, Inc. (NASDAQ: PIXY) 36% HIGHER; For the third quarter of fiscal 2018, the company expects to report that gross billings more than doubled to $60.2 million, compared to $27.5 million for the 2017 third quarter, that revenues increased 102.6% to $9.4 million, compared to $4.6 million for the third quarter of 2017, that gross profit was $1.5 million versus $0.6 million in the prior year period, and that net loss per share was 6 cents during the quarter, an improvement over the net loss of 11 cents in the prior year... More

Credit Suisse Remains Bullish on Johnson & Johnson (JNJ) as Lawsuits Increase Attention

July 13, 2018 7:41 AM EDT

Credit Suisse reiterated an Outperform rating and $151.00 price target on Johnson & Johnson (NYSE: JNJ) as the company has received an increasing number of investor inquiries in recent months on the numerous talcum and mesh lawsuits that JNJ is currently defending. Analyst Vamil Divan... More

Johnson & Johnson (JNJ) Says it's Deeply Disappointed in Verdict in St. Louis Trial

July 13, 2018 6:13 AM EDT

Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's verdict in the St. Louis court.

"Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process that allowed plaintiffs to present a... More

St. Louis Jury Returns $4.69 Billion Verdict Against J&J (JNJ) in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer

July 13, 2018 6:12 AM EDT

A jury has awarded $4.69 billion to 22 women and their families who alleged that decades of daily use of Johnson & Johnson's (NYSE: JNJ) asbestos-laden talcum powder products caused their ovarian cancer.

The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning the verdict. The jury award includes $550 million in compensatory damages and $4.14 billion in punitive damages against the company.

While there have been other trials in which juries have determined that talc products contained... More

Johnson & Johnson (JNJ) jury awards $4.1 billion in punitive damages over talc cancer - Bloomberg

July 12, 2018 6:36 PM EDT

Johnson & Johnson (NYSE: JNJ) jury awards $4.1 billion in punitive damages over talc cancer - Bloomberg

... More

Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case

July 12, 2018 4:36 PM EDT

By Tina Bellon

(Reuters) - A Missouri jury on Thursday ordered Johnson & Johnson (NYSE: JNJ) to pay a record $4.69 billion to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

The verdict is the largest J&J has faced to date over allegations that its talc-based products cause cancer.

The company is battling some 9,000 talc cases. J&J denies both that its talc products cause cancer and that they ever contained asbestos. It says decades of studies show its... More

Johnson & Johnson (JNJ) Loses St. Louis Trial Over Talc Asbestos Cancer Claims - Bloomberg

July 12, 2018 3:37 PM EDT

Johnson & Johnson (NYSE: JNJ) Loses St. Louis Trial Over Talc Asbestos Cancer Claims - Bloomberg

... More

Goldman Sachs Upgrades Johnson & Johnson (JNJ) to Neutral

July 12, 2018 6:13 AM EDT

Goldman Sachs upgraded Johnson & Johnson (NYSE: JNJ) from Sell to Neutral with a price target of $134.00 (from $127.00).

Analyst Jami Rubin notes shares are down 10% YTD and 15% from all-time highs. The firm's downgrade to Sell in September 2017 was largely driven by valuation with... More